Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)
China · Delayed Price · Currency is CNY 26.56
-0.24 (-0.90%)
Apr 9, 2026, 3:00 PM CST
SHA:600196 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 40,972 | 40,396 | 40,911 | 43,377 | 38,666 |
Other Revenue | 689.21 | 671.23 | 488.71 | 574.48 | 345.58 |
| 41,662 | 41,067 | 41,400 | 43,952 | 39,011 | |
Revenue Growth (YoY) | 1.45% | -0.80% | -5.81% | 12.66% | 28.72% |
Cost of Revenue | 20,878 | 21,426 | 21,717 | 23,256 | 20,294 |
Gross Profit | 20,784 | 19,641 | 19,683 | 20,696 | 18,717 |
Selling, General & Admin | 13,777 | 12,963 | 14,087 | 12,999 | 12,328 |
Research & Development | 4,013 | 3,644 | 4,346 | 4,302 | 3,837 |
Other Operating Expenses | 81.12 | -47.52 | -44.99 | -88.15 | -57.86 |
Operating Expenses | 17,993 | 16,668 | 18,499 | 17,275 | 16,180 |
Operating Income | 2,790 | 2,974 | 1,184 | 3,420 | 2,537 |
Interest Expense | -1,265 | -1,432 | -1,325 | -963.81 | -822.54 |
Interest & Investment Income | 4,064 | 2,478 | 3,866 | 4,660 | 4,858 |
Currency Exchange Gain (Loss) | -152.16 | -13.36 | 13.03 | 62.36 | 154.63 |
Other Non Operating Income (Expenses) | -38.46 | -41.41 | -57.73 | -31.78 | -31.06 |
EBT Excluding Unusual Items | 5,398 | 3,965 | 3,680 | 7,147 | 6,695 |
Impairment of Goodwill | - | - | - | -180 | -150 |
Gain (Loss) on Sale of Investments | -362.6 | -115.94 | -488.66 | -2,498 | -110.19 |
Gain (Loss) on Sale of Assets | 69.35 | 371.01 | 5.56 | 125.6 | -15.42 |
Asset Writedown | -41.64 | -57.93 | -42.14 | -20.48 | -171.01 |
Other Unusual Items | 48.09 | -5.44 | 109.38 | 0.25 | -206.16 |
Pretax Income | 5,112 | 4,169 | 3,265 | 4,574 | 6,043 |
Income Tax Expense | 864.05 | 656.84 | 369.5 | 626.92 | 1,066 |
Earnings From Continuing Operations | 4,248 | 3,512 | 2,895 | 3,947 | 4,976 |
Minority Interest in Earnings | -877.37 | -742.55 | -508.8 | -216.66 | -247.56 |
Net Income | 3,371 | 2,770 | 2,386 | 3,731 | 4,729 |
Preferred Dividends & Other Adjustments | - | - | 1.05 | - | - |
Net Income to Common | 3,371 | 2,770 | 2,385 | 3,731 | 4,729 |
Net Income Growth | 21.69% | 16.08% | -36.04% | -21.10% | 29.10% |
Shares Outstanding (Basic) | 2,646 | 2,670 | 2,670 | 2,607 | 2,563 |
Shares Outstanding (Diluted) | 2,646 | 2,670 | 2,670 | 2,607 | 2,563 |
Shares Change (YoY) | -0.90% | 0.02% | 2.40% | 1.74% | - |
EPS (Basic) | 1.27 | 1.04 | 0.89 | 1.43 | 1.85 |
EPS (Diluted) | 1.27 | 1.04 | 0.89 | 1.43 | 1.85 |
EPS Growth | 22.44% | 16.10% | -37.52% | -22.50% | 29.10% |
Free Cash Flow | 764.78 | 66.79 | -1,922 | -1,671 | -1,035 |
Free Cash Flow Per Share | 0.29 | 0.03 | -0.72 | -0.64 | -0.40 |
Dividend Per Share | 0.390 | 0.320 | 0.270 | 0.420 | 0.560 |
Dividend Growth | 21.88% | 18.52% | -35.71% | -25.00% | 30.23% |
Gross Margin | 49.89% | 47.83% | 47.54% | 47.09% | 47.98% |
Operating Margin | 6.70% | 7.24% | 2.86% | 7.78% | 6.50% |
Profit Margin | 8.09% | 6.74% | 5.76% | 8.49% | 12.12% |
Free Cash Flow Margin | 1.84% | 0.16% | -4.64% | -3.80% | -2.65% |
EBITDA | 5,883 | 5,556 | 3,883 | 5,541 | 4,184 |
EBITDA Margin | 14.12% | 13.53% | 9.38% | 12.61% | 10.72% |
D&A For EBITDA | 3,093 | 2,582 | 2,699 | 2,121 | 1,647 |
EBIT | 2,790 | 2,974 | 1,184 | 3,420 | 2,537 |
EBIT Margin | 6.70% | 7.24% | 2.86% | 7.78% | 6.50% |
Effective Tax Rate | 16.90% | 15.75% | 11.32% | 13.71% | 17.65% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.